Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia
BMC Cancer volume 6, Article number: 172 (2006)
Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ AML. We conducted a retrospective multicenter study of 12 children treated with GO on a compassionate basis (median age 5.5 y). Three patients (2 MDS/AML, 1 JMML) were refractory to first-line treatment, 8 patients with de novo AML were in refractory first relapse, and one patient with de novo AML was in 2nd relapse after stem cell transplantation (SCT). CD33 expression exceeded 20% in all cases.
GO was administered alone, at a unit dose of 3–9 mg/m2, once (3 patients), twice (3 patients), three (5 patients) or five times (1 patient). Mean follow-up was 128 days (8–585 d).
There were three complete responses (25%) leading to further curative treatment (SCT). Treatment failed in the other nine patients, and only one patient was alive at the end of follow-up. NCI-CTC grade III/IV adverse events comprised hematological toxicity (n = 12), hypertransaminasemia (n = 2), allergy and hyperbilirubinemia (1 case each). There was only one major adverse event (grade IV allergy). No case of sinusoidal obstruction syndrome occurred.
These results warrant a prospective trial of GO in a larger population of children with AML.
Despite gradual improvements over the years, the survival rate among children with acute myeloblastic leukemia (AML) was only 50 to 60% during the last decade [1–6]. About 10% of children do not enter first complete remission (CR). In addition, second CR is often difficult to achieve, even with high-dose cytarabine. Patients who relapse therefore have few therapeutic options. New cytotoxic agents, including nucleoside analogs, are currently being evaluated [2, 7–9].
An alternative to chemotherapy (CT) is to target leukemic blasts with monoclonal antibodies. Approximately 80% to 90% of pediatric AML patients have myeloid blast cells that express the CD33 surface antigen . This antigen is present on normal hematopoietic progenitor cells but not on normal hematopoietic stem cells or on non hematopoietic cells . Gemtuzumab ozogamicin (GO) is an immunoconjugate consisting of a humanized anti-CD33 IgG4κ antibody linked to the cytotoxic compound N-acetyl-γ-calicheamicin dimethylhydrazine, a member of the enediyne antitumor antibiotic family [12, 13]. GO selectively targets CD33+ cells and was specifically developed for the treatment of AML. After receptor binding, the complex is rapidly internalized and calicheamicin is released intracellularly. Calicheamicins are known for their extreme cytotoxic potency, attributed to double-stranded DNA cleavage at specific sequences [14, 15]. In phase I/II studies, approximately 30% of adults with relapsed AML responded to GO [12, 13, 16]. Severe myelosuppression is common, however, and platelet recovery can be slow, probably owing to CD33-expressing platelet precursor damage . Toxicity is relatively mild compared with classical multiagent CT, especially with regard to mucositis and infections , but GO can cause severe liver toxicity in the form of a sinusoidal obstruction syndrome (SOS) [18, 19] Several factors can increase the risk of hepatotoxicity, including previous stem cell transplantation (SCT) . Prior exposure to GO is also known to increase the risk of SOS in patients who subsequently undergo myeloablative SCT  GO has been approved in the United States for the treatment of elderly patients with relapsed AML .
GO has rarely been used in children. Sievers et al reported preliminary results of a phase I ascending-dose study of GO in 18 children with relapsed or refractory AML . Likewise, Zwaan et al used GO (up to three doses) to treat 15 children with relapsed/refractory CD33+ AML, on a compassionate-use basis [23, 24]. More recently Arceci et al reported a dose-escalation study of 29 children with multiple relapsed or primary refractory AML . Here we report our experience with GO monotherapy in 12 children with relapsed or refractory AML.
This retrospective study involved 12 children treated with GO between March 1999 and April 2004 on a compassionate-use basis in four pediatric centers. GO therapy was approved by the french agency for health product safety (AFSSAPS), and the guardians' and/or patients' informed consent was obtained. The cutoff date for this analysis was 30 September 2004. The children had myelodysplasia (MDS)/AML refractory to standard induction therapy (n = 2), juvenile myelomonocytic leukemia (JMML) refractory to several cytotoxic drugs and retinoic acid (n = 1), first relapse of AML refractory to reinduction therapy (n = 8), or AML in second relapse after SCT (n = 1).
The patients' characteristics at initial diagnosis are shown in Table 1. Median age was 5.5 years (1.0–17.2 y), and there were 7 boys and 5 girls. The initial diagnoses were de novo AML in 9 cases (M1 = 1; M2 = 2; M5 = 1, M6 = 1; M7 = 4), MDS/AML in 2 cases (M6 = 1; M7 = 1) and JMML in 1 case. FAB M6/M7 and transformed MDS were over-represented, reflecting the poor prognosis of these patients. The median white blood cell (WBC) count at diagnosis was 15.7 × 109/L (1.5–38.0 × 109/L). Cytogenetic analysis showed intermediate-risk AML in 8 cases and high-risk AML in 4 cases.
First-line CT was based on four different intensive regimens consisting of repeated courses of cytarabine plus intercalating agents. The patient with refractory JMML (Table 2, patient #1) received a combination of 6-mercaptopurine, etoposide, cytarabine, hydroxyurea and 6-thioguanine, plus 13 cis-retinoid acid, without responding. The two patients with primary refractory MDS/AML (patients #5 and #7) had received standard induction CT (cytarabine 200 mg/m2/d × 7 days plus mitoxantrone 12 mg/m2/d × 5 days), without responding. They were further treated with high-dose cytarabine and amsidine, but again no response was obtained. One of the two patients then received several courses of low-dose cytarabine plus etoposide before undergoing matched unrelated donor (MUD)-SCT while in partial remission. He relapsed 14 months later and was again refractory to low-dose cytarabine plus etoposide at the time of GO therapy.
The nine relapsing patients had been treated with FLAG (a combination of fludarabine, high-dose cytarabine and granulocyte colony-stimulating factor),  with or without anthracyclines. Eight of these nine patients (patients #2, #4, #6, #8, #9, #10, #11, #12) were in refractory reinduction CT before receiving GO. The ninth patient (UPN #3) entered CR2 after reinduction CT and underwent cord-blood SCT. This patient had no sign of active hepatic graft-versus-host disease or SOS and had normal transaminase and bilirubin values when GO was administered for very early post-SCT relapse.
The median interval between initial diagnosis and GO administration was 11.5 months (4.8–45.5 months). All patients had CD33+ myeloid leukemia at the time of GO therapy, with a median proportion of bone marrow blasts of 47% (20 – 98%). The median WBC count was 3.2 × 109/L (0.2–22.0 × 109/L). GO was given to 8 patients at a total dose of 9 mg/m2, administered in a single dose (n = 3) or divided into 3 doses given on days 1, 4 and 7 (n = 5). Patient #9 received 5 doses of 3 mg/m2 (days 1, 4, 7, 28 and 31). Patient #10 received two doses of 9 mg/m2 each (days 1 and 14). Patient #11 received two doses of 7.5 mg/m2 each (days 1 and 16). Patient #12 received one dose of 6 mg/m2 (day 1) and another dose of 9 mg/m2 (day 16) (see Table 2). The unit doses and dosing intervals were based on those used in adults and in the pediatric studies of Sievers et al  and Zwaan et al , and were decided on by the physicians in charge of each patient. Fractionated doses were adopted secondarily, as they were reported to be associated with less SOS in adults (Raffoux E et al, annual meeting of the french hematologic society SFH, 2000, abstract). This schedule was chosen in the ongoing french MyloFrance protocol in adults.
Complete responses to GO were defined on the basis of the following consensus criteria: a bone marrow blast proportion of 5% or less, in the absence of leukemic cells in peripheral blood or elsewhere. The definition of CR included adequate recovery of peripheral blood cell counts (granulocytes > 1 × 109/L and platelets > 100 × 109/L with at least one week of transfusion independence). CRp was defined as a response with incomplete platelet recovery but with platelet transfusion independence . Adverse events are reported according to the National Cancer Institute common toxicity criteria (NCI-CTC; 2003 revision) .
Responses and major toxicities are summarized in Table 2.
Median follow-up after the beginning of GO treatment was 128 days (8–585 d). As shown in Table 2, responses were observed in 3 (25%) of the 12 patients. One patient entered CR on day 39, after 5 doses of 3 mg/m2, and two patients entered CRp, on day 28 after 3 doses of 3 mg/m2 and on day 24 after 2 doses of 7.5 mg/m2. No change in bone marrow blast count was observed in two patients on day 15. Six patients progressed before day 15 of GO therapy. Patient #10 had paucicellular bone marrow, with few leukemic blasts, on day 66.
The three responding patients subsequently received SCT. Patient #5 received MUD-SCT 83 days after the first GO infusion and died on day 260 from infectious complications of SCT. Patient #9 received three GO doses of 3 mg/m2, which reduced the proportion of bone marrow blasts from 86% at baseline to 20% on day 28. Because GO was well tolerated, two more doses of 3 mg/m2 GO were given, and CR2 was achieved on day 39. The patient relapsed 6.5 months after MUD-SCT. Further GO therapy controlled the bone marrow blast count, with no significant adverse effects, for 12.5 months after SCT. The patient finally died in blast crisis after a cumulative GO dose of approximately 45 mg/m2. Patient #11 received haplo-SCT 72 days after the first GO infusion. Bone marrow relapse occurred 9.6 months after SCT and the patient died 11.2 months after SCT. CR or CRp was maintained for 205, 260 and 288 days in the three responding patients.
Two patients (#4 and #6) who received three GO doses of 3 mg/m2 (on days 1, 4 and 7) had no change in their bone marrow blast counts on day 15. They died of disease progression 97 and 101 days after the first GO infusion. Five patients (#1, #2, #3, #7 and #8) who progressed less than 15 days after GO treatment initiation developed grade IV hematologic toxicity related to the underlying leukemia. Patient #2 died from disease progression on day 8 after GO initiation. The remaining four patients received palliative therapy and died a median of 116 days after GO initiation. Patient #10, who did not respond to GO by day 66 (paucicellular bone marrow, with a few leukemic blasts) also developed grade IV hematologic toxicity probably related to the underlying disease. He died in blast crisis 238 days after GO initiation. Patient #12 did not respond by day 31, after two doses of GO (day 1 = 6 mg/m2, day 16 = 9 mg/m2). He then received alternative treatments and was alive in partial remission 120 days after GO administration. MUD-SCT was scheduled one month later.
Only one of the 12 patients was alive at the cutoff date for this analysis.
In the three responding patients (#5, #9, #11), GO was well tolerated, with the exception of NCI-CTC grade III-IV hematologic toxicity. Patient #1 developed severe infusion-related hypotension (NCI-CTC grade IV) and fever, necessitating fluid support. Three other patients had febrile reactions during GO infusion (patients #7, #8 and #12). Five patients (#4, #7, #8, #11 and #12) had grade II vomiting during the infusion or the subsequent 24 hours. Two patients (#4 and #6) had grade II stomatitis, but the cause (GO or prolonged neutropenia?) was not determined. Four patients developed secondary infections: patient #7 had preseptic shock on day 12, but no bacterial or fungal pathogen was identified; patient #10 developed acute cholecystitis; and patients #3 and #4 had grade III febrile neutropenia with no identified site of infection. Patients #1 and #3 had transient NCI-CTC grade III transaminase elevation, accompanied by transient grade IV hyperbilirubinemia in one case (patient #1), but without ascites or weight gain suggestive of SOS. None of the 12 patients developed SOS.
We treated 12 children with relapsed or refractory myeloid leukemia with GO (3–18 mg/m2, up to 5 infusions) on a compassionate-use basis. The prognosis of such children is very poor: three of our patients with newly diagnosed JMML or MDS/AML were refractory to several different induction regimens; the remaining nine patients were either refractory to reinduction therapy or in second relapse after SCT. Further use of intensive CT is limited by its toxicity [28, 29].
GO monotherapy thus yielded a response rate of 25% (3/12 patients). This rate is similar to that obtained in adults with relapsed AML [12, 13]. However, available adult studies only included patients in first AML relapse. As in our series, the 15 children treated by Zwaan et al and the 29 children treated by Arceci et al with GO monotherapy had more advanced disease and, potentially, more cumulative toxicities [23, 25]. Two CRp was followed by SCT in the Zwaan et al's series, and the two children were alive without significant GO/SCT-related toxicity, albeit with short follow-up (6 and 9 months). Likewise, our three patients who entered CR or CRp subsequently underwent SCT, and no major hepatotoxicity occurred. CR or CRp was maintained for 7 to 10 months before death or further relapse. In the dose-escalation study reported by Arceci et al, 4 patients experienced CR and 4 experienced CRp, for 8 (28%) overall remissions after GO therapy. Response rates were comparable in patients with refractory (30%) and relapsed (26%) disease. Most patients died of progressive disease (22/29), unfortunatly comprising 4/8 patients in CR or CRp after GO. These data suggest a need for intensive therapy following GO-induced remission, as in adults .
Considering the toxicity of GO, NCI-CTC grade IV hematologic toxicity occurred in all 12 children of our series. In responders, it was probably related to expression of the CD33 target by normal bone marrow progenitors. In non responders, it was difficult to determine the respective roles of GO and the underlying leukemia. With regard to non hematologic adverse events, GO was relatively well tolerated compared to intensive CT, with no cases of mucositis and only one noteworthy infection. This is in keeping with previous pediatric results [23, 25]. GO therapy is an established risk factor for SOS [18–20]. No cases of SOS occurred in our series, even after SCT in the three responding patients. Zwaan et al reported only one case of SOS among 15 GO-treated children, occurring after SCT . Arceci et al described an 24% overall incidence of SOS . SOS developed in 6 of 7 patients after they underwent SCT. They had been exposed to GO within 3.5 to 4 months of transplantation. Two other patients who underwent SCT more than 4 months from GO exposure did not developed SOS. These findings are consistent with similar adult series . Taken together, these data suggest that the time from treatment with GO to SCT for refractory/relapsed AML appears to be important with respect to the incidence of SOS after SCT. The incidence of liver dysfunction in GO-treated children is similar to that observed in the largest adult series , in which liver dysfunction was generally transient and never life-threatening.
GO was well tolerated, even during repeated infusions. One of our patients (#9) received a cumulative dose of approximately 45 mg/m2 over a 14-month period. One patient in Zwaan's series was treated repeatedly with GO, with relatively long intervals between the infusions, and responded each time without showing signs of additional toxicity . Palliative treatment thus appears to be feasible with repeated GO infusions.
This report confirms that GO is clinically active in children with relapsed/refractory CD33+ AML. Despite its good tolerability, GO monotherapy only induces a response rate of 25 to 33%, similar to that previously reported in adults. In a recent trial, GO was combined with intensive CT as first-line treatment for AML in 72 patients aged 17 from 59 years . Certain schedules of CT-GO combination induction therapy yielded CR in 91% of patients, 78% of whom were in continuous CR at 8 months. GO should be tested prospectively in a larger population of children with AML, with more stringent eligibility criteria and treatment schedules, in association with CT.
Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E, Masera G, Rondelli R, Zanesco L, Mandelli F: Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol. 1993, 11: 1046-54.
Behar C, Suciu S, Benoit Y, Robert A, Vilmer E, Boutard P, Bertrand Y, Lutz P, Ferster A, Tokaji E, Manel AM, Solbu G, Otten J: Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872. Med Pediatr Oncol. 1996, 26: 173-9. 10.1002/(SICI)1096-911X(199603)26:3<173::AID-MPO5>3.0.CO;2-H.
Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996, 87: 4979-89.
Stevens RF, Hann IM, Wheatley K, Gray RG: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998, 101: 130-40. 10.1046/j.1365-2141.1998.00677.x.
Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jurgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H: Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001, 19: 2705-13.
Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B, Gandemer V, Schmitt C, Lamagnere JP, De Lumley L, Bader-Meunier B, Couillaud G, Schaison G, Landman-Parker J, Thuret I, Dalle JH, Baruchel A, Leverger G: Group LAME of the French Society of Pediatric Hematology and Immunology. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. J Clin Oncol. 2002, 20: 2774-82. 10.1200/JCO.2002.07.300.
Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ, Kim K, Mosher DF, Wiersma SR, Longo WL: Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma. 2001, 41: 321-31.
Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL: A phase I trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol. 1991, 9: 416-22.
Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL: 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992, 10: 364-70.
Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H, Riehm H, Schellong G, Ludwig WD: Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 1995, 86: 3097-108.
Andrews RG, Singer JW, Bernstein ID: Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989, 169: 1721-31. 10.1084/jem.169.5.1721.
Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999, 93: 3678-84.
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study Group: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001, 19: 3244-54.
Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002, 13: 47-58. 10.1021/bc010021y.
Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993, 53: 3336-42.
Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001, 7: 1490-6.
Leopold LH, Berger MS, Feingold J: Acute and long-term toxicities associated with gemtuzumab ozogamicin (mylotarg®) therapy of acute myeloid leukemia. Clin Lymphoma. 2002, 2 (suppl): S29-34.
Rajvanshi P, Shulman HM, Sievers EL, McDonald GB: Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002, 99: 2310-4. 10.1182/blood.V99.7.2310.
Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001, 92: 406-13. 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U.
Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA: Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002, 30: 23-28. 10.1038/sj.bmt.1703602.
Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Antin EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003, 102: 1578-82. 10.1182/blood-2003-01-0255.
Sievers EL, Arceci R, Franklin J: Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg, CMA-676) in pediatric patients with acute myeloid leukemia. Blood. 2000, 96: 217b-(Abstr.)
Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, Kaspers GJ: Gemtuzumab ozogamicin: first clinical experience in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003, 101: 3868-71. 10.1182/blood-2002-07-1947.
Reinhardt D, Diekamp S, Fleischhack G, Corbacioglu C, Jurgens H, Dworzak M, Kaspers G, Creutzig U, Zwaan CM: Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie. 2004, 27: 269-72. 10.1159/000075606.
Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL: Safety and efficacy of gemtuzumab ozogamicin (Mylotarg(R)) in pediatric patients with advanced CD33-positive acute myeloid leukemia. Blood. 2005, 106: 1183-8. 10.1182/blood-2004-10-3821.
McCarthy AJ, Pitcher LA, Hann IM, Oakhill A: FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol. 1999, 32: 411-15. 10.1002/(SICI)1096-911X(199906)32:6<411::AID-MPO3>3.0.CO;2-K.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0 DCTC, National Cancer Institute, National Institutes of Health, Department of Health and Human services, March 31, 2003.
Fleischhack G, Hasan C, Graf N, Mann G, Bode U: IDA-FLAG (idarubicine, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998, 102: 647-645. 10.1046/j.1365-2141.1998.00836.x.
Webb DKH: Management of relapsed acute myeloid leukaemia. Br J Haematol. 1999, 106: 851-9. 10.1046/j.1365-2141.1999.01629.x.
Larson RA, Sievers ER, Stadtmauer EA: A final analysis of the efficacy ans safety of gemtuzumab ozogamicin in 277 patients with acute myeloid leukemia in first relapse. Blood. 2002, 100: 338a-(Abstr.)
Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003, 102: 4277-83. 10.1182/blood-2003-05-1620.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/172/prepub
The autor(s) declare that they have no competing interests.
Conception and design: BB, AB, GL; analysis and interpretation of data: BB, AA, CG, KY, TL, YB, GL, AB; drafting the article or revising it critically for important intellectual content: AB, GL, BB, AA; final approval of the version to be published: all authors.
About this article
Cite this article
Brethon, B., Auvrignon, A., Galambrun, C. et al. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia. BMC Cancer 6, 172 (2006). https://doi.org/10.1186/1471-2407-6-172